- Chief Medical Editor’s Page
- AREDS2: Substituting Lutein and Zeaxanthin for Beta-Carotene May Be Warranted
- Attending Annual Meetings Virtually
- It Takes a Village (of ODs) …
- Reassessing the Applicability of Low Vision Services
- The Low Vision Exam: Integrating a Functional Approach
- Implantable Miniature Telescope
- Premium Services: a Conversion Rate Study With Consideration to Sex and Age
- OCT: What’s Now and What’s Next?
- Unraveling the Mystery Behind Allergic Conjunctivitis
- Talk to Your Patient, Doc!
- The Dry Eye “Butterfly” Effect
- Advanced Medical Therapy for DED
- Latest Technologies in the Diagnosis of DED and OSD
- DED: You Are the Expert
- Dry Eye Disease: Not All Artificial Tears Are the Same
- Dry Eye: The Forgotten
- Strategies for Managing Difficult-to-Treat DED
- Using Social Media Effectively to Promote Your Eye Care Practice
- Education for Physicians and Patients: Best Practices
- Multispectral Imaging: A Revolution in Retinal Diagnosis and Health Assessment
- Industry News and Innovations
- Recognizing the Hallmark Signs of a Rare Corneal Dystrophy
The Retinal Health Assessment (RHA, Annidis Health Systems Corp.) is a multispectral imaging (MSI) device that is useful for the early detection of optic nerve and retinal disease. It features advanced imaging modalities that allow users to differentiate and follow a wide variety of complex eye conditions and diseases. This instrument differs from other retinal imaging in that it employs an extensive range of discreet monochromatic light sources to create a series of en face fundus spectral sections throughout the thickness of the retina and choroid.1 The images are captured in a few seconds and reveal detailed views of a variety of retinal and choroidal structures, allowing for very early diagnosis and easier differentiation of occult or overlapping pathology.
Images can be captured in the screening mode through anatomically small or undilated pupils or in the full diagnostic mode through small or dilated pupils. Image quality is maintained through small pupils using a low-light xenon flash that is applied to the retina during image acquisition. The screening mode is designed to survey the deep retina for early pathological change during routine examinations or as part of a pretesting workup (Figure 1). The diagnostic mode provides clinicians the ability to differentiate and follow pathology. The diagnostic modality provides additional images captured through a broader spectral range (Figure 2).
One of the instrument’s biggest advantages is that it can provide a high-resolution, en face view of the retinal pigment epithelium (RPE) and the deep retinal structures not commonly seen with conventional noninvasive imaging techniques or ophthalmoscopy (see Pathologies Revealed and Differentiation With the RHA). The RPE has a high metabolic rate and is considered to be one of the most important structures in the maintenance of retinal health. Visualization, early detection, and monitoring of changes in the RPE enhances a clinician’s ability to educate, counsel, and devise treatment for patients.
The RHA does more than image the RPE, however. The instrument is capable of performing an in-depth retinal health screening and a comprehensive diagnostic analysis that allows for the detection and differentiation of a wide variety of retinal, retinal vascular, choroidal vascular, and optic nerve disorders.
Functionality: How Does the Instrument Work?
MSI entails the use of an extensive range of discrete monochromatic light sources, with each one capable of penetrating or fluorescing different light-absorbing species or chromophores throughout the layers of the retina and choroid (Figure 3). For example, long wavelength light (beyond 600 nm) is used to spectrally reveal melanin, and a slightly longer wavelength is used to reveal liposfuscin. The instrument also provides differential views of the superficial retina, the nerve fiber layer, RPE (Figure 4) , sub-RPE, choroid, and the retinal and choroidal vasculature by using individual and combination wavelengths ranging from 533 to 850 nm that are selectively absorbed by hemoglobin, melanin, and macular pigments (xanthophyles).
The Clinical Value Of RPE Visualization
Visualization of the RPE structure is essential in primary care screening because it is the clinical origin point of many retinal diseases. For example, the diagnosis of age-related macular degeneration (AMD) depends on signs in the retina (drusen is typically the hallmark of the early disease stages) regardless of visual acuity. Additionally, drusen can represent a late-stage finding of RPE pathology, so direct examination of the RPE is critical for both early detection and the classification of AMD.2 Moreover, research such as the Rotterdam Age Related Maculopathy Study shows that the combination of RPE melanin disruptions combined with the appearance of drusen are associated with a 5-fold increase in the risk of developing exudative AMD over 5 years.3
In a primary eye care setting, visualization of the RPE (both melanin and lipofuscin) may provide clinicians with a greater capacity to monitor early changes in this metabolically active structure of the eye. Based on findings from imaging the RPE and choroid, clinicians may choose to counsel patients earlier or more aggressively regarding diet and modifiable risk factors. More importantly, as genetic testing, nutriceutical, pharmaceutical, and ophthalmic lens technology research continues to reveal therapeutic treatments for RPE disease, visualizing the RPE independent of other structures for the signs of early changes might become routine standard of care in targeted populations.4,5
MSI may also have applications for monitoring conditions that affect the melanin pigment in the RPE, including:
- acquired and hereditary retinal diseases and lesions with pathogenesis rooted in melanin dysfunction or proliferation (eg, nevi, melanoma, congenital hypertrophy of the RPE, retinitis pigmentosa, neurofibromatosis);
- pre- and postlaser treatment for diabetic macular edema, because melanin in the RPE represents the single most important source of heat in thermal photocoagulation; and
- monitoring of potentially retinotoxic drugs such as chloroquine and certain phenothiazine derivatives, which have an affinity for melanin.
The clinical utility of visualizing the RPE is to gauge the retina’s health and to improve early diagnostic accuracy and treatment. MSI provides en face fundus spectral slices of the retina. In addition to its utility for clinicians who specialize in retinal pathologies, the RHA has applications for the primary care clinical setting. Because visualization of melanin, lipofuscin, and hemoglobin is achievable, the primary care clinician can screen for early atypical changes in targeted populations as part of a comprehensive eye examination. With MSI technology, there is a means to monitor the RPE of patients with risk factors indicating a likelihood of developing degenerative changes (ie, family history of AMD, family history of genetic disorder, smoking) or retinal pigmentary toxicities. Likewise, the mapping of both oxygenated and deoxygenated hemoglobin provides optometrists with a noninvasive tool for differentiating a number of retinal and choroidal vascular maladies, such as endovascular leakage, macular edema, and retinal, choroidal, and optic nerve hypoperfusion. Additional features like the stereo anaglyph map allow for early screening and baseline documentation of the optic nerve. The RHA has broad application in the diagnosis of optic nerve and retinal disease, making it a potentially quintessential tool in optometric practice.
Section Editor Eric T. Brooker, OD, is in private practice at the Advanced Vision Institute, Las Vegas. He has no financial interest in the product and company mentioned herein. Dr. Brooker may be reached at (949) 241-9077; firstname.lastname@example.org.
Dorothy Hitchmoth, OD, is chief of optometry and director of residency at the VAMC White River Junction, Vermont; owns Hitchmoth Eyecare Associates; is CEO of New England Telehealth; and is the director of the Annidis Center of Excellence. She is a consultant for Annidis Health Systems Corp. Dr. Hitchmoth may be reached at email@example.com.
- Everdell NL, Styles IB, Calcagni A, et al. Multispectral imaging of the ocular fundus using light emitting diode Illumination. Rev Sci Instrum. 2010;81(9):093706.
- Sohrab MA, Smith RT, Fawzi AA. Imaging characteristics of dry-age related macular degeneration. Semin Ophthalmol. 2011;26(3):156-166.
- Van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of age related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch of Ophthal. 2003;121:519-526.
- Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology. 2003; 110(2):392-399.
- Williams DR. Autofluorescence imaging of the RPE cell mosaic in the Living Eye. Asso for Research and Vision in Ophthalmology abstract, 2010. Fundus Autofluorescence: Perspectives and New Directions Mini Symposium.